Drexel University8d
Orphaned Again: Revisiting the Orphan Drug Act and Prioritizing Patient Access to Medicine
In 1983, Congress passed the Orphan Drug Act (“ODA”) as part of an effort to provide market incentives for pharmaceutical manufacturers to produce “orphan drugs,” drugs for diseases that ...
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
Scientific publications and reach in the field have shown already that post-injury angiogenesis and vascular remodeling ...
Fierce Pharma2d
Argenx's Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts
Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...
GlobalData on MSN3d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...
Pharmaceutical Technology8d
Orphan drugs: How to avoid costly stock losses in Europe
With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial
PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
Healio2d
FDA grants fast track designation to X-linked retinoschisis treatment
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...